Evidence Explainer · Drugs & supplements
Spermidine did not improve the trial’s primary memory outcome
In the 12-month SmartAge trial, a wheat-germ spermidine extract did not improve the prespecified memory outcome or secondary outcomes. Exploratory signals do not establish dementia prevention or longer life.
By Lois Rune
Published August 4, 2026 · Updated August 5, 2026 · AI-assistance disclosure
The larger trial did not confirm the early signal
An earlier three-month pilot raised interest. In the larger, longer SmartAge phase 2b trial, the intention-to-treat primary memory comparison was null and prespecified secondary outcomes were also null.
What was tested
One 0.9 mg/day wheat-germ-derived extract for 12 months.
What led
The null prespecified result—not exploratory subgroup findings.
What remains unknown
Dementia prevention, broad cognitive benefit, long-term safety, healthspan and lifespan.
The bottom line
SmartAge randomized 100 older adults with subjective cognitive decline. The wheat-germ-derived supplement did not improve mnemonic discrimination versus placebo: the between-group difference was −0.03 (95% CI −0.11 to 0.05; P=.47). Prespecified secondary outcomes were also null.
What researchers did
Adults age 60 to 90 at one German center received a standardized extract supplying 0.9 mg spermidine per day or microcrystalline-cellulose placebo for 12 months. The analysis was intention to treat; 89 participants completed the intervention.
What they found
The primary result and prespecified secondary outcomes did not differ significantly. Exploratory per-protocol and subgroup analyses suggested possible verbal-memory and inflammation signals, but those analyses were not the prespecified primary test and require independent confirmation.
How strong is the evidence?
A randomized, double-masked trial is stronger than the preceding 30-person pilot. The larger trial’s null primary result should lead. A separate 12-person pharmacokinetic study using 15 mg/day for five days did not raise plasma or salivary spermidine, although plasma spermine increased; it did not test cognition.
What this does not show
The study does not show dementia prevention, cognitive rejuvenation, disability prevention, slower biological aging, longer healthspan or longer life. It also does not validate spermidine-rich diets or every retail supplement.
Safety, regulation and conflicts
Adverse events were balanced during 12 months, which cannot establish uncommon or long-term harms. FDA does not approve dietary supplements for safety or effectiveness before sale. Several authors disclosed equity, executive or advisory roles, patents, or former equity involving Longevity Labs GmbH, which supported extract development.
What happens next
A larger independently led trial would need to preregister a clinically meaningful cognitive outcome, reproduce it across populations and doses, and follow participants long enough to assess durability and safety. Exploratory SmartAge signals are hypotheses for that work.
Educational boundary
This article does not recommend spermidine, a dose, a product or a supplement regimen. Do not use a pilot signal or exploratory subgroup to replace clinical evaluation or infer that a marketed product prevents dementia.
Sources, roles and limits
- SmartAge phase 2b trial (PMID 35616942) — primary randomized cognitive-outcome evidence
- SmartAge protocol (PMID 31039826) — prespecified design and outcome context
- ClinicalTrials.gov NCT03094546 — registry status; no posted results as of verification
- Earlier SmartAge pilot (PMID 30388439) — small preliminary context, not confirmation
- Spermidine pharmacokinetic trial (PMID 37111071) — dose and metabolism uncertainty, not cognitive efficacy
- FDA dietary-supplement overview — current regulation and safety context
Compare cognitive tests with clinical outcomes
Browse plain-language topics · Compare interventions · Study library · Trial tracker
More stories that separate cognitive signals from prevention
Another supplement story separating test movement from dementia prevention
Multivitamins moved some tests and aging clocks. What does that mean?
COSMOS found small cognitive-test differences and modest movement in two DNA-methylation clocks; neither establishes dementia prevention or longer life.
Evidence scopeHuman cognitive tests and biomarkers · correlated randomized substudies
A larger randomized cognition trial with an active comparison
The MIND diet trial found no cognitive edge over its active control
Both groups improved with counseling and calorie restriction; the between-group cognitive difference was not significant and MRI measures were similar.
Evidence scopeHuman cognition and MRI · randomized dietary trial
Long follow-up showing why practiced skills are not survival
Cognitive training improved practiced skills—not survival or proven dementia prevention
ACTIVE supports trained-ability gains and some function signals, found no mortality benefit, and leaves a claims-based dementia subgroup methodologically disputed.
Evidence scopeHuman trained abilities and long-term outcomes · randomized trial plus disputed secondary analysis
Disclosures and history
- August 4, 2026 — source discovery and independent verification completed before prose drafting.
- August 4, 2026 — identifiers, population, product, endpoint hierarchy, limitations, counterevidence, safety and funding reviewed claim by claim.
- Reviewed under standing publication authorization; release remains conditional on exact-head editorial, accessibility, responsive, container, deployment and production gates.
- AI-assisted research and drafting; source boundaries and final publication state are governed by the MoreYears.news editorial process.
- Corrections: no linked correction, retraction or expression of concern was identified for the featured primary record as of verification; sources will be rechecked at release and when this story is updated.